Sesen Bio, Inc. (SESN) |
0.6288 0.043 (7.29%) 03-07 16:00 |
Open: | 0.5732 |
High: | 0.6288 |
Low: | 0.57 |
Volume: | 1,782,290 |
Market Cap: | 128(M) |
PE Ratio: | -6.29 |
Exchange: | NASDAQ Capital Market |
Industry: | Biotechnology |
Sector: | Healthcare |
Technical analysis | ||||
sell | buy |
Resistance 2: | 0.75 |
Resistance 1: | 0.64 |
Pivot price: | 0.60 |
Support 1: | 0.57 |
Support 2: | 0.52 |
52w High: | 0.965 |
52w Low: | 0.365 |
Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. Its lead product candidates include Vicineum, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer; to treat non-muscle invasive carcinoma in situ of the bladder in patients previously treated with BCG; and for the treatment of squamous cell carcinoma of the head and neck, as well as VB6-845d, a product candidate for use in the treatment of various types of an anti-epithelial cell adhesion molecule-positive solid tumors. Sesen Bio, Inc. has an agreement with Leiden University Medical Center to co-develop an imaging agent. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
EPS | -0.191 |
Book Value | -0.070 |
PEG Ratio | 0.00 |
Gross Profit | 0.006 |
Profit Margin (%) | -5.61 |
Operating Margin (%) | -43.29 |
Return on Assets (ttm) | -7.5 |
Return on Equity (ttm) | -2.1 |
Tue, 02 Apr 2024
SESEN BIO, INC. (SESN) Dips More Than Broader Markets: What You Should Know - Yahoo Movies Canada
Tue, 07 Mar 2023
Carisma Therapeutics Closes Merger with Sesen Bio - PR Newswire
Thu, 02 Mar 2023
Sesen Bio Stockholders Approve Merger with Carisma Therapeutics - Business Wire
Mon, 06 Feb 2023
Sesen Bio (NASDAQ:SESN) investors are sitting on a loss of 37% if they invested three years ago - Yahoo Finance
Mon, 30 Jan 2023
Sesen Bio Receives NASDAQ Delisting Notice - Business Wire
Wed, 21 Sep 2022
Novartis, Moderna Partner Agrees To Merge With Beleaguered Sesen Bio - Yahoo Finance
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |